Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
1.30
Dollar change
+0.06
Percentage change
4.84
%
Index- P/E- EPS (ttm)-1.95 Insider Own34.34% Shs Outstand58.95M Perf Week8.33%
Market Cap78.12M Forward P/E- EPS next Y-1.72 Insider Trans8.65% Shs Float39.46M Perf Month5.69%
Income-112.67M PEG- EPS next Q-0.45 Inst Own31.11% Short Float1.69% Perf Quarter2.36%
Sales6.29M P/S12.42 EPS this Y13.46% Inst Trans-2.23% Short Ratio2.64 Perf Half Y4.00%
Book/sh2.70 P/B0.48 EPS next Y-2.12% ROA-44.34% Short Interest0.67M Perf Year-8.45%
Cash/sh2.88 P/C0.45 EPS next 5Y- ROE-55.84% 52W Range0.73 - 2.29 Perf YTD4.00%
Dividend Est.- P/FCF- EPS past 5Y-72.78% ROI-61.08% 52W High-43.23% Beta1.82
Dividend TTM- Quick Ratio7.24 Sales past 5Y0.00% Gross Margin47.19% 52W Low77.84% ATR (14)0.11
Dividend Ex-Date- Current Ratio7.24 EPS Y/Y TTM17.69% Oper. Margin-1891.38% RSI (14)59.51 Volatility8.45% 10.98%
Employees63 Debt/Eq0.18 Sales Y/Y TTM- Profit Margin-1791.87% Recom1.00 Target Price4.25
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q22.73% Payout- Rel Volume1.23 Prev Close1.24
Sales Surprise49.90% EPS Surprise18.10% Sales Q/Q- EarningsMar 21 BMO Avg Volume253.18K Price1.30
SMA2011.11% SMA5015.25% SMA200-0.93% Trades Volume312,497 Change4.84%
Date Action Analyst Rating Change Price Target Change
Sep-14-22Initiated Berenberg Buy $12
Oct-20-21Resumed Cowen Outperform
Jun-24-21Initiated H.C. Wainwright Buy $35
Nov-03-20Initiated Piper Sandler Overweight $50
Nov-03-20Initiated Jefferies Buy $36
Nov-03-20Initiated Goldman Buy $45
Nov-03-20Initiated Cowen Outperform
Mar-27-24 12:00PM
Mar-21-24 01:53PM
07:05AM
Mar-07-24 04:05PM
Mar-05-24 04:44PM
04:05PM Loading…
Feb-27-24 04:05PM
Jan-25-24 08:00AM
Dec-18-23 04:06PM
Dec-04-23 08:00AM
Nov-27-23 04:05PM
Nov-13-23 05:25PM
04:05PM
Nov-02-23 04:05PM
12:00PM
Oct-27-23 08:00AM
12:30PM Loading…
Oct-13-23 12:30PM
Oct-04-23 04:05PM
Aug-17-23 08:00AM
Aug-08-23 05:50PM
04:05PM
Jul-19-23 07:27AM
Jun-06-23 08:00AM
Jun-01-23 04:05PM
May-12-23 07:00AM
May-10-23 05:35PM
04:05PM
Apr-24-23 04:05PM
Apr-18-23 02:24PM
Apr-11-23 04:05PM
Mar-15-23 04:05PM
04:05PM Loading…
Feb-28-23 04:05PM
Jan-09-23 09:25AM
08:23AM
07:00AM
Dec-20-22 10:28AM
Dec-12-22 09:35AM
Dec-11-22 10:00AM
Dec-07-22 04:05PM
Nov-22-22 04:05PM
09:35AM
Nov-09-22 12:04PM
Nov-08-22 04:10PM
04:05PM
Oct-12-22 04:04AM
Sep-06-22 04:05PM
Aug-22-22 11:33AM
08:00AM
Aug-16-22 04:05PM
Aug-09-22 09:55AM
Aug-04-22 04:05PM
Jul-25-22 08:48AM
Jul-10-22 10:27AM
Jul-08-22 12:00PM
Jun-10-22 03:04AM
Jun-01-22 04:05PM
May-22-22 08:04AM
May-17-22 07:00AM
May-12-22 10:23AM
May-06-22 12:23PM
May-04-22 04:05PM
Apr-08-22 01:07PM
Mar-08-22 05:08PM
Mar-01-22 07:00AM
Feb-24-22 04:05PM
Feb-01-22 04:05PM
Jan-31-22 01:45PM
Dec-17-21 08:00AM
Dec-09-21 10:15AM
Dec-06-21 07:00AM
Nov-29-21 07:00AM
Nov-24-21 07:00AM
Nov-11-21 04:05PM
Nov-09-21 04:10PM
Nov-08-21 04:44PM
Nov-04-21 07:00AM
Oct-11-21 09:41AM
Oct-05-21 12:17PM
Sep-30-21 04:36PM
Sep-14-21 08:00AM
Sep-07-21 07:00AM
Aug-12-21 04:05PM
Jul-27-21 05:36PM
08:00AM
Jul-12-21 04:56AM
May-26-21 08:00AM
May-25-21 08:00AM
May-11-21 04:05PM
May-06-21 08:00AM
Apr-11-21 05:53AM
Apr-10-21 08:30AM
Mar-31-21 11:25AM
Mar-26-21 08:00AM
Mar-23-21 04:05PM
Mar-10-21 04:35PM
Mar-04-21 08:12AM
07:00AM
Feb-25-21 08:00AM
Feb-22-21 08:00AM
Jan-26-21 08:00AM
Jan-11-21 02:46AM
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Frisbee AllisonSR VP, CORP OPERATIONS & LEGALFeb 21 '24Sale1.0512,10512,757204,510Feb 23 08:04 PM
Lin Charles YSR VP, RESEARCH & DEVELOPMENTFeb 21 '24Sale1.0512,03612,685234,603Feb 23 08:07 PM
Olek Elizabeth ASR VP, CLINICAL SCIENCEFeb 21 '24Sale1.057,3687,765193,275Feb 23 08:12 PM
DiMartino JorgeChief Medical Officer & VPJan 04 '24Sale1.1812,00914,214315,246Jan 05 06:27 PM
Kosacz BarbaraCOO & General CounselJan 04 '24Sale1.1810,67612,636928,966Jan 05 06:26 PM
Dinsmore ChristopherChief Scientific OfficerJan 04 '24Sale1.187,3668,718260,969Jan 05 06:30 PM
DiMartino JorgeChief Medical Officer & VPDec 12 '23Sale1.3017,36722,664327,255Dec 13 04:09 PM
Dinsmore ChristopherChief Scientific OfficerDec 12 '23Sale1.3010,03213,092268,335Dec 13 04:10 PM
BISCHOFBERGER NORBERT WPresident & CEONov 17 '23Buy1.0897,935106,1622,540,665Nov 17 05:41 PM
BISCHOFBERGER NORBERT WPresident & CEONov 16 '23Buy1.00262,433261,5142,442,730Nov 17 05:41 PM
BISCHOFBERGER NORBERT WPresident & CEONov 15 '23Buy0.801,370,6881,102,7182,180,297Nov 17 05:41 PM
DiMartino JorgeChief Medical Officer & VPJul 06 '23Sale1.7510,81818,956344,622Jul 07 04:07 PM
Al-Wakeel Yasir B.Chief Financial OfficerJul 06 '23Sale1.759,61716,852346,102Jul 07 04:06 PM
Dinsmore ChristopherChief Scientific OfficerJul 06 '23Sale1.756,63411,625278,367Jul 07 04:08 PM